imodium instant suus dispergeeruv tablett
mcneil healthcare (ireland) limited - loperamiid - suus dispergeeruv tablett - 2mg 20tk; 2mg 10tk; 2mg 6tk
loperamide-grindeks kõvakapsel
grindeks as - loperamiid - kõvakapsel - 2mg 10tk
loperamid-ratiopharm 2 mg õhukese polümeerikattega tablett
ratiopharm gmbh - loperamiid - õhukese polümeerikattega tablett - 2mg 10tk
lopacut õhukese polümeerikattega tablett
vitabalans oy - loperamiid - õhukese polümeerikattega tablett - 2mg 8tk
imodium kõvakapsel
mcneil healthcare (ireland) limited - loperamiid - kõvakapsel - 2mg 20tk; 2mg 6tk
tammex kõvakapsel
dh-norm s.r.o. - loperamiid - kõvakapsel - 2mg 10tk; 2mg 20tk
zokinvy
eigerbio europe limited - lonafarnib - progeria; laminopathies - muud alimentary seedetrakti ja ainevahetust tooted, - zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of hutchinson-gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous lmna mutation with progerin-like protein accumulation or a homozygous or compound heterozygous zmpste24 mutation.
verzenios
eli lilly nederland b.v. - abemaciclib - rinnanäärmed - antineoplastilised ained - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.
irinotecan teva infusioonilahuse kontsentraat
teva pharma b.v. - irinotekaan - infusioonilahuse kontsentraat - 20mg 1ml 25ml 5tk; 20mg 1ml 2ml 5tk; 20mg 1ml 5ml 1tk; 20mg 1ml 2ml 1tk; 20mg 1ml 5ml 5tk; 20mg 1ml 15ml 5tk; 20mg 1ml 25ml 1tk
irinotecan csc infusioonilahuse kontsentraat
gp-pharm s.a. - irinotekaan - infusioonilahuse kontsentraat - 20mg 1ml 15ml 1tk; 20mg 1ml 5ml 1tk; 20mg 1ml 2ml 1tk; 20mg 1ml 25ml 1tk